EOHILIA Dosing for Eosinophilic Esophagitis
For adults and patients 11 years and older with EoE, prescribe EOHILIA (budesonide oral suspension) 2 mg twice daily for induction therapy, taken once in the morning and once in the evening for 12 weeks. 1
Induction Therapy Dosing
The FDA-approved dose is 2 mg (one 10 mL packet) twice daily for all patients 11 years and older 1. This dosing achieved:
- 53.1% stringent histologic response (≤6 eos/hpf) versus 1.0% with placebo
- 52.6% symptom response versus 39.1% with placebo
- Significant improvements in endoscopic severity scores 2
Critical Administration Instructions
EOHILIA must be taken on an empty stomach with specific timing requirements 1:
- Do NOT mix with food or liquid
- Shake packet for at least 10 seconds before opening
- Squeeze entire contents directly into mouth
- Swallow all suspension without mixing
- Wait 30 minutes before eating or drinking anything
- After 30 minutes, rinse mouth with water and spit out (do not swallow) to reduce candidiasis risk
Maintenance Therapy Considerations
While EOHILIA is FDA-approved only for 12-week induction therapy 1, the 2022 British guidelines strongly support maintenance treatment given high relapse rates after withdrawal 3. Phase 3 data showed maintenance dosing of 0.5 mg or 1.0 mg twice daily maintained remission in 73.5-75% of patients versus 4.4% with placebo over 48 weeks 3.
Important caveat: The FDA label explicitly states EOHILIA "has not been shown to be safe and effective for the treatment of EoE for longer than 12 weeks" 1. However, clinical practice often requires ongoing therapy due to disease chronicity.
Pediatric Dosing Nuances
For children under 11 years (off-label use), the British guidelines recommend oral viscous budesonide formulations 3:
- 1 mg/day if <150 cm height
- 2 mg/day if ≥150 cm height
- Can be given as single dose or divided twice daily
- Higher doses (4 mg/day) used for non-responders >150 cm or >11 years old
Key Safety Monitoring
- Oropharyngeal/esophageal candidiasis is the most common adverse event (up to 22% of patients) 3
- Monitor for adrenal suppression, particularly with prolonged use—9% developed abnormal ACTH-stimulated cortisol after 12 weeks 1
- Avoid grapefruit juice during therapy (increases budesonide levels) 1
- Dose reduction needed in moderate hepatic impairment (3.5-fold higher exposure) 1
Common Prescribing Pitfalls
- Taking with food: Reduces efficacy by altering mucosal contact time—must emphasize fasting administration
- Swallowing rinse water: Increases systemic absorption and candidiasis risk
- Premature discontinuation: Disease relapses in >95% within 87 days of stopping therapy 3
- Not monitoring for erosive esophagitis: Incidence increases from 2.2% to 13% during therapy; consider PPI co-administration 4
The evidence strongly supports budesonide oral suspension as first-line pharmacologic therapy for EoE, with the orodispersible formulation preferred in adults per European guidelines due to superior maintenance data 3.